These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27391309)

  • 1. Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m(2) for definitive radiochemotherapy of locally advanced head-and-neck cancers.
    Rades D; Seidl D; Janssen S; Bajrovic A; Karner K; Strojan P; Schild SE
    BMC Cancer; 2016 Jul; 16():437. PubMed ID: 27391309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
    Rades D; Strojan P; Seidl D; Janssen S; Bajrovic A; Kazic N; Hakim SG; Wollenberg B; Schild SE
    J Craniomaxillofac Surg; 2016 Sep; 44(9):1436-40. PubMed ID: 27499514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?
    Rades D; Seidl D; Janssen S; Bajrovic A; Hakim SG; Wollenberg B; Karner K; Strojan P; Schild SE
    Oral Oncol; 2016 Aug; 59():67-72. PubMed ID: 27424184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer.
    Seidl D; Janssen S; Strojan P; Bajrovic A; Schild SE; Rades D
    Anticancer Res; 2016 May; 36(5):2523-6. PubMed ID: 27127167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity.
    Rades D; Ulbricht T; Hakim SG; Schild SE
    Strahlenther Onkol; 2012 Jan; 188(1):42-8. PubMed ID: 22194029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.
    Mackiewicz J; Rybarczyk-Kasiuchnicz A; Łasińska I; Mazur-Roszak M; Świniuch D; Michalak M; Kaźmierska J; Studniarek A; Krokowicz Ł; Bajon T
    Medicine (Baltimore); 2017 Dec; 96(51):e9151. PubMed ID: 29390445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma.
    Al-Mamgani A; de Ridder M; Navran A; Klop WM; de Boer JP; Tesselaar ME
    Eur Arch Otorhinolaryngol; 2017 Oct; 274(10):3757-3765. PubMed ID: 28755023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis.
    Rades D; Kronemann S; Meyners T; Schild SE; Hakim SG
    Oral Oncol; 2010 Jul; 46(7):549-52. PubMed ID: 20435508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer.
    Espeli V; Zucca E; Ghielmini M; Giannini O; Salatino A; Martucci F; Richetti A
    Oral Oncol; 2012 Mar; 48(3):266-71. PubMed ID: 22079100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
    Noronha V; Joshi A; Patil VM; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; D'Cruz AK; Banavali S; Pai PS; Chaturvedi P; Chaukar D; Pande N; Chandrasekharan A; Talreja V; Vallathol DH; Mathrudev V; Manjrekar A; Maske K; Bhelekar AS; Nawale K; Kannan S; Gota V; Bhattacharjee A; Kane S; Juvekar SL; Prabhash K
    J Clin Oncol; 2018 Apr; 36(11):1064-1072. PubMed ID: 29220295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis.
    Pala M; Odrazka K; Holeckova P; Vitek P; Kubes J; Dvorak J; Podlesak T
    J BUON; 2012; 17(3):471-7. PubMed ID: 23033284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers.
    Rades D; Seidl D; Janssen S; Strojan P; Karner K; Bajrovic A; Hakim SG; Wollenberg B; Schild SE
    Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):1021-1027. PubMed ID: 27687678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.
    Lee SY; Choi YS; Song IC; Park SG; Keam B; Yang YJ; Song EK; Lee HJ; Cho SH; Shim H; Park KU; Lee KH; Jo DY; Jo IS; Yun HJ;
    Medicine (Baltimore); 2018 May; 97(21):e10778. PubMed ID: 29794758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
    Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.
    Urba S; Gatz J; Shen W; Hossain A; Winfree K; Koustenis A; Peterson P; Cohen EE
    Oral Oncol; 2012 Aug; 48(8):723-9. PubMed ID: 22414289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
    Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
    Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
    Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis.
    Steinmann D; Cerny B; Karstens JH; Bremer M
    Strahlenther Onkol; 2009 Oct; 185(10):682-8. PubMed ID: 19806334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.